

Siegfried at a glance

expect
more

About us

Siegfried at a glance



Siegfried at a glance – a globally leading CDMO

PRODUCTION OF

Active Pharmaceutical Ingredients
and Finished Dosage Forms



HEADQUARTERED IN

Zofingen (CH)

PUBLICLY LISTED

since **1973** 

NUMBER OF SITES GLOBALLY



12 7 x API, 5x FDF
thereof 2 in Spain

EXPAND GLOBAL REVENUE 2023 (CHF)



>1.2bn

GROWTH SINCE 2010



>300%



CUSTOMERS

>500



FTES

~3.700



QUALITY


Impeccable
track record

[Watch Corporate Movie](#)

Siegfried

Our offering along the value chain


We offer integrated supply of **APIs and finished products**.



Bringing together our 150 years **pharma and chemical heritage**, we offer as an integrated partner benefit to our customers with more synergy, expertise and value.



Our production network offers a unique combination of flexibility and integration for both, innovative an generic products



Zofingen	Switzerland	1
DS Development & Manufacturing		
Pennsville	USA	2
DS Manufacturing		
Hal Far	Malta	3
DP Manufacturing		
Irvine	USA	4
DP Manufacturing		
Nantong	China	5
DS Development & Manufacturing		
Hamel	Germany	6
DP Development & Manufacturing		
Minden	Germany	7
DS Manufacturing		
Evionnaz	Switzerland	8
DS Development & Manufacturing		
St. Vulbas	France	9
DS Manufacturing		
Barberà del Vallès	Spain	10
DP Development & Manufacturing		
El Masnou	Spain	11
DP Development & Manufacturing		

Our mission
Our vision
Our values

Siegfried at a glance



Our mission: We do matter to customers, patients and society

«With mastery of science and technology, we take the precious innovations of our pharmaceutical customers to industrial scale and manufacture safe drugs for patients worldwide»

Our vision: We aim for industry leadership

«Siegfried is the most trusted partner of the pharmaceutical industry and the global leader in the CDMO space – because...



...we are the strongest team running the most competitive network»

Our values: We strive for outstanding performance

«Our values and leadership principles are the basis to build the strongest team in the industry»



Excellence

«We excel in everything we do»



Passion

«We deeply care ybout what we do and how we do it»



Integrity

«We act responsibly, reliably, respectfully and live up to our own standards»



Quality



«We do it right first time»



Sustainability

«We do not only think about tomorrow, but far beyond»

Our leadership values are the basis to build the strongest team in the industry



Our history


Siegfried at a glance



Our history

1873

Pharmacist **Samuel Benoni Siegfried** founded a company with 12 employees as a supplier to pharmacies



1904

Conversion into a joint stock corporation

1928

Founding of Ganes Chemical Works, Inc. (NJ, USA)

1973

Quotation on the Swiss Stock Exchange (SWX) in Basel

1991

Focus on custom development and manufacturing

2001

Building of two core divisions:

- > Siegfried und Sidroga
- > Integration of Ganes into the Siegfried Group = Siegfried (USA) Inc.

2005

Acquisition der Penick Corporation in New Jersey (USA)

2007

- > Launch of a new pharmaceutical production facility in Malta
- > Sale of the Sidroga division
- > Sale of the biotech activities

2008

Sale of the pharmaceutical production site in Zofingen



Our history

2012

Acquisition of Alliance Medical Products (AMP) in Irvine (CA, USA)



2013

Construction of a new production site in Nantong (CN) and a new production building in Zofingen (CH)



2014

Acquisition of Hameln Pharma in Hameln (DE)

2015

Acquisition of BASF sites in Minden (DE), Evionnaz (CH) und St. Vulbas (FR)

2021

Acquisition of two pharmaceutical production sites from Novartis in Barberà del Vallès and El Masnou (ES)



2023


Acquisition of a majority stake in DiNAMIQS, a Swiss-based biotechnology company

From 2010: «Transform» strategy

From 2016: «Evolve» strategy

Our management

Siegfried at a glance



Management – Board of Directors



Dr. Andreas Casutt
CHAIRMAN



Dr. Alexandra Brand



Prof. Dr. Wolfram Carius



Elodie Carr-Cingari



Dr. Martin Schmid



Dr. Beat Walti



Isabelle Welton

Management – Executive Committee



Dr. Wolfgang Wienand
CHIEF EXECUTIVE OFFICER



Dr. Reto Suter
CHIEF FINANCIAL OFFICER



Marcel Imwinkelried
CHIEF OPERATING OFFICER
DRUG PRODUCTS



Henrik Krüpper
CHIEF OPERATING OFFICER
DRUG SUBSTANCES



Dr. Jürgen Roos
CHIEF SCIENTIFIC OFFICER



Marianne Späne
CHIEF BUSINESS OFFICER DRUG
SUBSTANCES AND DRUG PRODUCTS



Irene Wosgien
CHIEF HUMAN RESOURCES OFFICER


Our business model

Siegfried at a glance





Drug Substances



APIs, intermediates
controlled substances



Drug Products

Solid dosage forms
(including capsules for inhalation)

Semi-solid dosage forms
(ophthalmic ointments)

Liquid dosage forms
(sterile and non-sterile)


Our financials

Siegfried at a glance



Net sales

Net sales split 2023




32.4%
Drug Products

67.6%
Drug Substances

CHF million	2023	2022	Change
Drug Substances	860.0	753.7	↗ +14.1% (+16.8% in LC)
Drug Products	411.5	475.8	↗ -13.5% (-10.4% in LC)
Total	1 271.5	1 229.5	↗ +3.4% (+6.3% in LC)

Business development


Net sales (in million CHF)



Business development


Share Price Development

from January 1, 2019, to December 31, 2023



Sustainability

Siegfried at a glance



We do not only think about tomorrow, but far beyond

Siegfried started its ESG journey years ago:

- > Code of Business Conduct
- > Global Quality Policy
- > Resource and waste management
- > Safety initiatives



Cross-functional ESG Governance Board sponsored by CEO and supervised by BoD



Commitment:

Siegfried's carbon footprint to be reduced by 50% until 2030 compared to 2020¹



Global initiatives proliferating best practices



Introduction of Siegfried's supplier integrity commitment



¹ Normalized against Sales

Our ambitions to be an ESG leader in the CDMO market

Steps towards our ambition



Energy target

-10%

Target achieved: total energy consumption reduction in 2023¹



Renewable electricity

71%

71% of our electricity comes from renewable energy sources



Lost time accidents

-11%

Lost time injuries rate was reduced by 11% compared to 2022



Carbon footprint commitment³

-50%

Carbon footprint to be reduced by 50% until 2030²

Our most important distinctions

MSCI
ESG RATINGS



CCC B BB BBB A AA AAA

Confirmed on
12.2.23

Member of
Dow Jones
Sustainability Indices

Powered by the S&P Global CSA



Further planned activities

Improve ESG audit and 3rd party recognition / scoring

Collaborate with customers to reduce the environmental footprint of the production process

Add strengthened KPIs for water, resources and waste

Verify scope 3 emissions in full detail as part of CDP reporting in 2024

¹ Compared to 2021

² Compared to 2020, CO₂ equivalents normalized against sales

³ Scope 1, 2

Siegfried

expect more

CONTACT US

Head Office Siegfried AG
Untere Bruehlstrasse 4
4800 Zofingen Switzerland

Tel. +41 62 746 11 11
info@siegfried.ch
www.siegfried.ch

